SG Americas Securities LLC Buys 14,423 Shares of AnaptysBio, Inc. $ANAB

SG Americas Securities LLC increased its stake in AnaptysBio, Inc. (NASDAQ:ANAB) by 138.3% during the first quarter, Holdings Channel.com reports. The fund owned 24,851 shares of the biotechnology company’s stock after buying an additional 14,423 shares during the period. SG Americas Securities LLC’s holdings in AnaptysBio were worth $1,378,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Smartleaf Asset Management LLC increased its position in AnaptysBio by 5,864.3% during the 4th quarter. Smartleaf Asset Management LLC now owns 835 shares of the biotechnology company’s stock valued at $40,000 after purchasing an additional 821 shares during the period. Larson Financial Group LLC raised its holdings in AnaptysBio by 54.6% during the 3rd quarter. Larson Financial Group LLC now owns 1,340 shares of the biotechnology company’s stock worth $41,000 after purchasing an additional 473 shares during the last quarter. Tower Research Capital LLC TRC lifted its position in shares of AnaptysBio by 175.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 2,164 shares of the biotechnology company’s stock worth $48,000 after purchasing an additional 1,377 shares during the period. Osaic Holdings Inc. lifted its position in shares of AnaptysBio by 11,630.0% in the 2nd quarter. Osaic Holdings Inc. now owns 2,346 shares of the biotechnology company’s stock worth $52,000 after purchasing an additional 2,326 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of AnaptysBio by 24.3% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,345 shares of the biotechnology company’s stock valued at $65,000 after purchasing an additional 263 shares during the last quarter.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the stock. Barclays increased their price objective on shares of AnaptysBio from $63.00 to $75.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 13th. Wedbush upped their price target on shares of AnaptysBio from $60.00 to $75.00 and gave the company an “outperform” rating in a research report on Thursday, March 12th. UBS Group increased their price target on AnaptysBio from $60.00 to $76.00 and gave the stock a “buy” rating in a report on Wednesday, May 13th. Leerink Partners set a $90.00 price objective on AnaptysBio in a research report on Friday, May 15th. Finally, Weiss Ratings downgraded AnaptysBio from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, May 13th. Ten investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $81.82.

AnaptysBio Price Performance

Shares of ANAB stock opened at $63.42 on Friday. The firm has a 50 day moving average of $59.81 and a 200-day moving average of $56.29. The company has a market cap of $1.88 billion, a price-to-earnings ratio of -58.72 and a beta of 0.68. AnaptysBio, Inc. has a 52 week low of $11.40 and a 52 week high of $72.36.

AnaptysBio (NASDAQ:ANAB) last released its earnings results on Tuesday, May 12th. The biotechnology company reported ($1.84) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.64) by ($1.20). The company had revenue of $25.56 million for the quarter, compared to the consensus estimate of $18.86 million. Analysts anticipate that AnaptysBio, Inc. will post -1.35 earnings per share for the current year.

AnaptysBio declared that its Board of Directors has authorized a stock repurchase plan on Friday, March 27th that authorizes the company to buyback $100,000.00 billion in outstanding shares. This buyback authorization authorizes the biotechnology company to reacquire up to 5,352,316.2% of its stock through open market purchases. Stock buyback plans are usually a sign that the company’s management believes its shares are undervalued.

AnaptysBio Company Profile

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.